COMP <GO>
NRIX vs ABBV // RSI-14 & 200D SMA MOMENTUM
Nurix Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NRIX 3
— ABBV 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: NRIX
LAST: $26.80 (-1.18%) • MKT CAP: $2.96B
rsi-technicals
65.6
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRIX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NRIX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.89% | 3.47% | -12.36 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 54.00% | 8.60% | +45.40 | NRIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 5.33 | +4.19 | NRIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 65.6 | 65.1 | +0.50 | NRIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $513.86B | -$510.90B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NRIX REV | ABBV REV | NRIX GROSS % | ABBV GROSS % | NRIX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $84.0M | $61.16B | — | 70.2% | -$263.5M | $17.82B |
| FY 2024 | $54.5M | $56.33B | — | 70.0% | -$181.9M | $17.83B |
| FY 2023 | $77.0M | $54.32B | — | — | -$81.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRIX // BETA —
ABBV // BETA 1.15